In spite of their high lipophilicity and limited water solubility, the pharmacological, biological and preclinical safety profiles of these dual PI3K/mTOR inhibitors supported their clinical development and a few of them (NVP-BEZ235, for example) are currently undergoing phase I/II clinical trials in cancer patients [75]. This evidence concerns the gene MTOR and cancer.